Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
about
Nanoparticle ligand presentation for targeting solid tumors90Y-edotreotide for metastatic carcinoid refractory to octreotide.Detecting Tumor Metastases: The Road to Therapy Starts Here.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effects of intravenous amino a ...... (SMT487[OctreoTher) treatment.
@ast
Effects of intravenous amino a ...... (SMT487[OctreoTher) treatment.
@en
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide
@nl
type
label
Effects of intravenous amino a ...... (SMT487[OctreoTher) treatment.
@ast
Effects of intravenous amino a ...... (SMT487[OctreoTher) treatment.
@en
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide
@nl
prefLabel
Effects of intravenous amino a ...... (SMT487[OctreoTher) treatment.
@ast
Effects of intravenous amino a ...... (SMT487[OctreoTher) treatment.
@en
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide
@nl
P2093
P50
P1476
Effects of intravenous amino a ...... (SMT487[OctreoTher) treatment.
@en
P2093
Daniel Kahn
James Ponto
Mark Madsen
Mary Connolly
Sara Miller
Shayne Squires
Sue O'Dorisio
Thomas Carlisle
Wayne Walkner
P356
10.1089/108497804773391658
P577
2004-02-01T00:00:00Z